open access

Vol 6 (2021): Continuous Publishing
Original paper
Published online: 2021-12-30
Get Citation

Evaluation of hyper-reflective foci and their association with visual status in diabetic macular edema

Dharmendra Singh1, B.P. Guliani1, R.K. Duvesh1, Gayathri Priya1
·
Ophthalmol J 2021;6:232-240.
Affiliations
  1. Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

open access

Vol 6 (2021): Continuous Publishing
ORIGINAL PAPERS
Published online: 2021-12-30

Abstract

Background: This study aimed to know the association of visual status and hyperreflective foci in patients with diabetic macular edema (DME).

Material and methods: This observational cross-sectional study included patients with diabetes mellitus type 2 (DM2) with DME or non-proliferative diabetic retinopathy (NPDR). Baseline assessment included: ophthalmic examinations such as best-corrected visual acuity (LogMAR), color vision, contrast sensitivity, intraocular pressure (IOP), fundus examination by direct, indirect ophthalmoscopy, slit-lamp biomicroscopy with 90D, and spectraldomain — optical coherence tomography (SD-OCT) [counting of hyperreflective foci (HF) were done manually]. Retina specialists performed counting and classification of HF. The correlation was calculated to establish the association between HF with visual status. p-value < 0.05 was considered statistically significant.

Results: In majority of the patients (46.67%), HF was < 50 followed by 51–100 (30.83%) and > 100 (17.50%). With increasing HF, there was a significantly decreasing trend of best-corrected visual acuity (BCVA) (0.2 in no HF to 0.5 in HF > 100, p = 0.001) and contrast (1.58 in no HF to 1.35 in HF > 100, p = 0.0004). HF were found to significantly increase with increasing duration of the disease (4 in no HF to 17 in HF > 100, p = 0.0001). The lab parameters such as glycated haemoglobin (HbA1c), serum urea, serum creatinine, triglycerides, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) showed significant derangement with increasing HF (p < 0.05).

Conclusion: The presence of HF in patients with DME negatively affects BCVA and contrast sensitivity. The severity of HF may increase with the increasing duration of DME and altered glycemic index.

Abstract

Background: This study aimed to know the association of visual status and hyperreflective foci in patients with diabetic macular edema (DME).

Material and methods: This observational cross-sectional study included patients with diabetes mellitus type 2 (DM2) with DME or non-proliferative diabetic retinopathy (NPDR). Baseline assessment included: ophthalmic examinations such as best-corrected visual acuity (LogMAR), color vision, contrast sensitivity, intraocular pressure (IOP), fundus examination by direct, indirect ophthalmoscopy, slit-lamp biomicroscopy with 90D, and spectraldomain — optical coherence tomography (SD-OCT) [counting of hyperreflective foci (HF) were done manually]. Retina specialists performed counting and classification of HF. The correlation was calculated to establish the association between HF with visual status. p-value < 0.05 was considered statistically significant.

Results: In majority of the patients (46.67%), HF was < 50 followed by 51–100 (30.83%) and > 100 (17.50%). With increasing HF, there was a significantly decreasing trend of best-corrected visual acuity (BCVA) (0.2 in no HF to 0.5 in HF > 100, p = 0.001) and contrast (1.58 in no HF to 1.35 in HF > 100, p = 0.0004). HF were found to significantly increase with increasing duration of the disease (4 in no HF to 17 in HF > 100, p = 0.0001). The lab parameters such as glycated haemoglobin (HbA1c), serum urea, serum creatinine, triglycerides, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) showed significant derangement with increasing HF (p < 0.05).

Conclusion: The presence of HF in patients with DME negatively affects BCVA and contrast sensitivity. The severity of HF may increase with the increasing duration of DME and altered glycemic index.

Get Citation

Keywords

diabetic macular edema; hyperreflective foci; visual acuity

About this article
Title

Evaluation of hyper-reflective foci and their association with visual status in diabetic macular edema

Journal

Ophthalmology Journal

Issue

Vol 6 (2021): Continuous Publishing

Article type

Original paper

Pages

232-240

Published online

2021-12-30

Page views

5661

Article views/downloads

298

DOI

10.5603/OJ.2021.0037

Bibliographic record

Ophthalmol J 2021;6:232-240.

Keywords

diabetic macular edema
hyperreflective foci
visual acuity

Authors

Dharmendra Singh
B.P. Guliani
R.K. Duvesh
Gayathri Priya

References (25)
  1. Moss S. The 14-year incidence of visual loss in a diabetic population, Ophthalmology. 1998; 105(6): 998–1003.
  2. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995; 102(1): 7–16.
  3. Luxmi S, Ritika M, Lubna A, et al. Diabetic macular edema and its association to systemic risk factors in an urban north Indian population. J Clin Ophthalmol. 2018; 02(02).
  4. Murakami T, Tsujikawa A, Ohta M, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol. 2007; 143(1): 171–173.
  5. Lee H, Lee J, Chung H, et al. Baseline spectral domain optical coherence tomographic hyper reflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina. 2016; 36(7): 1372–1380.
  6. Chhablani JK, Kim JS, Cheng L, et al. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2012; 250(10): 1415–1420.
  7. Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical Coherence Tomographic Hyperreflective Foci. Ophthalmology. 2009; 116(5): 914–920.
  8. Standards of Medical Care in Diabetes. Diab Care. 2004; 28(Supplement 1): S4–S36.
  9. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7): 671–675.
  10. Schreur V, Altay L, van Asten F, et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One. 2018; 13(10): e0206482.
  11. Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina. 2016; 36(12): 2319–2328.
  12. Chung YR, Park SW, Choi SY, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017; 16(1): 4.
  13. Kim KT, Kim DY, Chae JuB. Association between Hyperreflective Foci on Spectral-Domain Optical Coherence Tomography and Early Recurrence of Diabetic Macular Edema after Intravitreal Dexamethasone Implantation. J Ophthalmol. 2019; 2019: 3459164.
  14. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012; 153(4): 710–7, 717.e1.
  15. Kang JW, Chung H, Chan Kim H. Correlation Of optical coherence tomographic hyperreflective foci with visual outcomes in different patterns of diabetic macular edema. Retina. 2016; 36(9): 1630–1639.
  16. Vujosevic S, Berton M, Bini S, et al. Hyperreflective retinal spots and visual function after anti-vascular endothelial growth factor treatment in center-involving diabetic macular edema. Retina. 2016; 36(7): 1298–1308.
  17. Berasategui B, Fonollosa A, Artaraz J, et al. Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study. BMC Ophthalmol. 2018; 18(1): 179.
  18. Shin YJ, Park KH, Hwang JM, et al. A novel color vision test for detection of diabetic macular edema. Invest Ophthalmol Vis Sci. 2014; 55(1): 25–32.
  19. Nixon DR, Flinn NAp. Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. Clin Ophthalmol. 2018; 12: 191–197.
  20. Echols BS, Clark ME, Swain TA, et al. Hyperreflective Foci and Specks Are Associated with Delayed Rod-Mediated Dark Adaptation in Nonneovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2020; 4(11): 1059–1068.
  21. Keane PA, Sadda SR. Predicting visual outcomes for macular disease using optical coherence tomography. Saudi J Ophthalmol. 2011; 25(2): 145–158.
  22. Abri Aghdam K, Pielen A, Framme C, et al. Correlation Between Hyperreflective Foci and Clinical Outcomes in Neovascular Age-Related Macular Degeneration After Switching to Aflibercept. Invest Ophthalmol Vis Sci. 2015; 56(11): 6448–6455.
  23. Davoudi S, Papavasileiou E, Roohipoor R, et al. Optical coherence tomography characteristics of macular edema and hard exudates and their association with lipid serum levels in type 2 diabetes. Retina. 2016; 36(9): 1622–1629.
  24. Wong BS, Sharanjeet-Kaur S, Ngah NF, et al. The Correlation between Hemoglobin A1c (HbA1c) and Hyperreflective Dots (HRD) in Diabetic Patients. Int J Environ Res Public Health. 2020; 17(9).
  25. Saxena S, Ruia S, Prasad S, et al. Increased serum levels of urea and creatinine are surrogate markers for disruption of retinal photoreceptor external limiting membrane and inner segment ellipsoid zone in type 2 diabetes mellitus. Retina. 2017; 37(2): 344–349.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Publisher: VM Media Group sp. z o.o., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 310 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl